AEGON ASSET MANAGEMENT UK Plc Decreases Stock Position in AbbVie Inc. $ABBV

AEGON ASSET MANAGEMENT UK Plc trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 11.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 523,472 shares of the company’s stock after selling 67,088 shares during the quarter. AbbVie accounts for approximately 1.4% of AEGON ASSET MANAGEMENT UK Plc’s investment portfolio, making the stock its 12th largest position. AEGON ASSET MANAGEMENT UK Plc’s holdings in AbbVie were worth $120,430,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Callahan Advisors LLC boosted its stake in shares of AbbVie by 3.0% during the 3rd quarter. Callahan Advisors LLC now owns 5,909 shares of the company’s stock worth $1,368,000 after purchasing an additional 172 shares during the period. Tufton Capital Management boosted its position in shares of AbbVie by 0.3% during the third quarter. Tufton Capital Management now owns 55,400 shares of the company’s stock valued at $12,827,000 after buying an additional 175 shares during the period. Copia Wealth Management grew its stake in shares of AbbVie by 240.7% during the third quarter. Copia Wealth Management now owns 368 shares of the company’s stock valued at $85,000 after buying an additional 260 shares during the last quarter. Avantax Planning Partners Inc. raised its holdings in shares of AbbVie by 0.9% in the third quarter. Avantax Planning Partners Inc. now owns 57,846 shares of the company’s stock worth $13,394,000 after buying an additional 541 shares during the period. Finally, Sage Rhino Capital LLC lifted its stake in shares of AbbVie by 5.4% during the 3rd quarter. Sage Rhino Capital LLC now owns 2,430 shares of the company’s stock worth $563,000 after acquiring an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $219.21 on Monday. The business has a fifty day moving average price of $225.60 and a 200-day moving average price of $217.60. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market capitalization of $387.42 billion, a price-to-earnings ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Morgan Stanley increased their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Guggenheim lifted their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $248.11.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.